The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Abstract
Background The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of first-line alemtuzumab compared with interferon beta 1a in a phase 3 trial.Methods In our 2 year, rater-masked, randomised controlled phase 3 trial, we enrolled adults aged 18-50 years with previously untreated relapsing-remitting multiple sclerosis. Eligible participants were randomly allocated in a 2:1 ratio by an interactive voice response system, stratified by site, to receive intravenous alemtuzumab 12 mg per day or subcutaneous interferon beta 1a 44 μg. Interferon beta 1a was given three-times per week and alemtuzumab was given once per day for 5 days at baseline and once per day for 3 days at 12 months. Coprimary endpoints were relapse rate and time to 6 month sustained accumulation of disability in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT00530348.Findings 187 (96%) of 195 patients randomly allocated interferon beta 1a and 376 (97%) of 386 patients randomly allocated alemtuzumab were included in the primary analyses. 75 (40%) patients in the interferon beta 1a group relapsed (122 events) compared with 82 (22%) patients in the alemtuzumab group (119 events; rate ratio 0·45 [95% CI 0·32-0·63]; p<0.0001), corresponding to a 54·9% improvement with alemtuzumab. Based on Kaplan-Meier estimates, 59% of patients in the interferon beta 1a group were relapse-free at 2 years compared with 78% of patients in the alemtuzumab group (p<0·0001). 20 (11%) of patients in the interferon beta 1a group had sustained accumulation of disability compared with 30 (8%) in the alemtuzumab group (hazard ratio 0·70 [95% CI 0·40-1·23]; p=0·22). 338 (90%) of patients in the alemtuzumab group had infusion-associated reactions; 12 (3%) of which were regarded as serious. Infections, predominantly of mild or moderate severity, occurred in 253 (67%) patients treated with alemtuzumab versus 85 (45%) patients treated with interferon beta 1a. 62 (16%) patients treated with alemtuzumab had herpes infections (predominantly cutaneous) compared with three (2%) patients treated with interferon beta 1a. By 24 months, 68 (18%) patients in the alemtuzumab group had thyroid-associated adverse events compared with 12 (6%) in the interferon beta 1a group, and three (1%) had immune thrombocytopenia compared with none in the interferon beta 1a group. Two patients in the alemtuzumab group developed thyroid papillary carcinoma.Interpretation Alemtuzumab's consistent safety profile and benefit in terms of reductions of relapse support its use for patients with previously untreated relapsing-remitting multiple sclerosis; however, benefit in terms of disability endpoints noted in previous trials was not observed here.Funding Genzyme (Sanofi) and Bayer Schering Pharma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the phase III clinical trials comparing alemtuzumab with interferon β-1a in highly active MS, no overall increase in malignancy was observed;”
From 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy (2019) · cites this paper as [60]
In the citing paper
“however, papillary thyroid cancer was discovered in 0.4% of alemtuzumab-treated patients [59, 60].”
From 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy (2019) · cites this paper as [60]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
Self-citationThe Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Multiple Comparison Procedures
Hochberg, Y., & Tamhane, A. C. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316672 · Cited by 2,389
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comı, G., Hartung, H., Khatri, B. O., Montalbán, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,220
Self-citationMultiple Comparison Procedures
Hahs-Vaughn, D., & Lomax, R. (2013) · Routledge eBooks · doi:10.4324/9780203137819-17 · Cited by 2,132
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E. W., LUBLIN, F. D., Weinstock‐Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,342
Self-citationDiagnostic criteria for multiple sclerosis
Poser, C. M., & Brinar, V. V. (2001) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(00)00125-6 · Cited by 1,282
Self-citationColes, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Self-citationDevelopment of a multiple sclerosis functional composite as a clinical trial outcome measure
Cutter, G. (1999) · Brain · doi:10.1093/brain/122.5.871 · Cited by 1,191
Cited by
Sorted by citations
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Diagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205
Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Self-citationMultiple Sclerosis: Current Knowledge and Future Outlook
Kamm, C. P., Uitdehaag, B. M. J., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,011
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Montalbán, X., Gold, R., Thompson, A. J., Otero‐Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comı, G., Derfuss, T. J., Fazekas, F., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517751049 · Cited by 739
Self-citationTiming of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
He, A. H., Merkel, B., Brown, J. W. L., Ryerson, L. Z., Kister, I., Malpas, C. B., Sharmin, S., Horáková, D., Havrdová, E., Spelman, T. D., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30067-3 · Cited by 491
Self-citationBrain health: time matters in multiple sclerosis
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S. S., Hobart, J. C., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A. L., & Vollmer, T. L. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.003 · Cited by 480
Self-citationMultiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
Harding, K. E., Williams, O., Willis, M., Hrastelj, J., Rimmer, A., Joseph, F., Tomassini, V., Wardle, M., Pickersgill, T. P., Robertson, N. P., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4905 · Cited by 377
Treatment of multiple sclerosis — success from bench to bedside
Tintoré, M., Vidal‐Jordana, Á., & Sastre‐Garriga, J. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0082-z · Cited by 357
Giovannoni, G., Sørensen, P. S., Cook, S. D., Rammohan, K. W., Rieckmann, P., Comı, G., Dangond, F., Adeniji, A. K., & Vermersch, P. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517727603 · Cited by 341
Self-citationMultiple sclerosis—a quiet revolution
Ransohoff, R. M., Hafler, D. A., & Lucchinetti, C. F. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.14 · Cited by 342
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Giovannoni, G., Turner, B. P., Gnanapavan, S., Offiah, C. E., Schmierer, K., & Marta, M. (2015) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.04.006 · Cited by 338
Self-citationBurt, R. K., Balabanov, R. D., Burman, J., Sharrack, B., Snowden, J. A., Oliveira, M. C., Fagius, J., ROSE, J. W., Nelson, F. M., Barreira, A. A., et al. (2019) · JAMA · doi:10.1001/jama.2018.18743 · Cited by 333
Evolving concepts in the treatment of relapsing multiple sclerosis
Comi, G., Radaelli, M., & Sørensen, P. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32388-1 · Cited by 320
Epidemiology and treatment of multiple sclerosis in elderly populations
Vaughn, C. B., Jakimovski, D., Kavak, K. S., Ramanathan, M. K., Benedict, R. H. B., Zivadinov, R., & Weinstock‐Guttman, B. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0183-3 · Cited by 320
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
Stefano, N. D., Airas, L. M., Grigoriadis, N., Mattle, H. P., O’Riordan, J. I., Oreja‐Guevara, C., Sellebjerg, F. T., Stankoff, B., Walczak, A., Wiendl, H., et al. (2014) · CNS Drugs · doi:10.1007/s40263-014-0140-z · Cited by 302
Sormani, M. P., Arnold, D. L., & Stefano, N. D. (2013) · Annals of Neurology · doi:10.1002/ana.24018 · Cited by 299
Self-citationVaisman‐Mentesh, A., Gutiérrez-González, M., DeKosky, B. J., & Wine, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01951 · Cited by 303
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
Baker, D., Marta, M., Pryce, G., Giovannoni, G., & Schmierer, K. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.01.042 · Cited by 290
Self-citationMelzer, N., Ruck, T., Fuhr, P., Gold, R., Hohlfeld, R., Marx, A., Melms, A., Tackenberg, B., Schalke, B. C. G., Schneider‐Gold, C., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8045-z · Cited by 305
Multiple Sclerosis: Immunopathology and Treatment Update
Dargahi, N., Κατσάρα, Μ., Tselios, T. V., Androutsou, M., de Courten, M., Matsoukas, J., & Apostolopoulos, V. (2017) · Brain Sciences · doi:10.3390/brainsci7070078 · Cited by 307
Disease‐modifying treatments for multiple sclerosis – a review of approved medications
Torkildsen, Ø., Myhr, K.-M., & Bø, L. (2015) · European Journal of Neurology · doi:10.1111/ene.12883 · Cited by 283
Cohen, J. A., Comı, G., Selmaj, K. W., Bar‐Or, A., Arnold, D. L., Steinman, L., Hartung, H., Montalbán, X., Havrdová, E., Cree, B., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30238-8 · Cited by 290
Self-citationAlemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H.-P., Havrdova, E., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004354 · Cited by 277
Self-citationon behalf of the MAGNIMS study group, Sastre‐Garriga, J., Pareto, D., Battaglini, M., Rocca, M. A., Ciccarelli, O., Enzinger, C., Wuerfel, J. T., Sormani, M. P., Barkhof, F., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0314-x · Cited by 292
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar‐Or, A., & Muraro, P. A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00498-5 · Cited by 284
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Gajofatto, A., & Benedetti, M. D. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i7.545 · Cited by 257
Disease-modifying therapies and infectious risks in multiple sclerosis
Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H., & Zettl, U. K. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.21 · Cited by 259
Self-citationSharrack, B., Saccardi, R., Alexander, T., Badoglio, M., Burman, J., Farge, D., Greco, R., Jessop, H., Kazmi, M. A., Киргизов, К. И., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0684-0 · Cited by 262
Comorbidity in multiple sclerosis: implications for patient care
Marrie, R. A. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.33 · Cited by 250
Overview of Infections in the Immunocompromised Host
Dropulic, L. K., & Lederman, H. M. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.dmih2-0026-2016 · Cited by 257
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
Baker, D., Herrod, S. S., Álvarez-González, C., Giovannoni, G., & Schmierer, K. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0676 · Cited by 242
Self-citationAlemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
Tuohy, O., Costelloe, L., Hill-Cawthorne, G., Bjornson, I., Harding, K., Robertson, N., May, K., Button, T., Azzopardi, L., Kousin-Ezewu, O., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307721 · Cited by 238
Self-citationHan, Y., Jia, Q., Jahani, P. S., Hurrell, B. P., Pan, C., Huang, P., Gukasyan, J., Woodward, N. C., Eskin, E., Gilliland, F. D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15649-3 · Cited by 222
Scolding, N. J., Barnes, D., Cader, S., Chataway, J., Chaudhuri, A., Coles, A. J., Giovannoni, G., Miller, D. H., Rashid, W., Schmierer, K., et al. (2015) · Practical Neurology · doi:10.1136/practneurol-2015-001139 · Cited by 222
Self-citationAlemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H.-P., Fox, E. J., Giovannoni, G., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004313 · Cited by 221
Self-citationECTRIMS / EAN guideline on the pharmacological treatment of people with multiple sclerosis
Montalbán, X., Gold, R., Thompson, A. J., Otero‐Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comı, G., Derfuss, T. J., Fazekas, F., et al. (2018) · European Journal of Neurology · doi:10.1111/ene.13536 · Cited by 233
Self-citationNatrajan, M. S., de la Fuente, A. G., Crawford, A. H., Linehan, E., Núñez, V., Johnson, K. R., Wu, T., Fitzgerald, D. C., Ricote, M., Bielekova, B., et al. (2015) · Brain · doi:10.1093/brain/awv289 · Cited by 225
McGuigan, C., Craner, M., Guadagno, J. V., Kapoor, R., Mazibrada, G., Molyneux, P. D., Nicholas, R. S., Palace, J. A., Pearson, O. R., Rog, D. J., et al. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311100 · Cited by 220
Tramacere, I., Giovane, C. D., Salanti, G., D’Amico, R., & Filippini, G. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011381.pub2 · Cited by 218
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
Ruck, T., Bittner, S., Wiendl, H., & Meuth, S. G. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160716414 · Cited by 224
Mikulska, M., Lanini, S., Gudiol, C., Drgoňa, Ľ., Ippolito, G., Fernández‐Ruiz, M., & Salzberger, B. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.003 · Cited by 215
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
Jones, J., Thompson, S. A. J., Loh, P., Davies, J. L., Tuohy, O., Curry, A. J., Azzopardi, L., Hill-Cawthorne, G. A., Fahey, M. T., Compston, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313654110 · Cited by 211
Self-citationBurt, R. K., Balabanov, R. D., Han, X., Sharrack, B., Morgan, A., Quigley, K., Yaung, K., Helenowski, I., Jovanovic, B., Spahovic, D., et al. (2015) · JAMA · doi:10.1001/jama.2014.17986 · Cited by 200
A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis
Marrie, R. A., Reider, N., Cohen, J. A., Stüve, O., Sørensen, P. S., Cutter, G., Reingold, S. C., & Trojano, M. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514564490 · Cited by 195
Self-citationOptimizing treatment success in multiple sclerosis
Ziemssen, T., Derfuss, T. J., Stefano, N. D., Giovannoni, G., Palavra, F., Tomic, D., Vollmer, T., & Schippling, S. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7986-y · Cited by 191
Self-citationInfectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E. K., Gedye, C. A., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 193
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod
Arvin, A. M., Wolinsky, J. S., Kappos, L., Morris, M. I., Reder, A. T., Tornatore, C., Gershon, A. A., Gershon, M. D., Levin, M. J., Bezuidenhoudt, M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3065 · Cited by 185
Havrdová, E., Horáková, D., & Kovářová, I. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285614563522 · Cited by 177
Neurodegeneration in multiple sclerosis
Mey, G. M., Mahajan, K. R., & DeSilva, T. M. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1583 · Cited by 188
Interferon β for Multiple SclerosisPreprint
Jakimovski, D., Kolb, C., Ramanathan, M. K., Zivadinov, R., & Weinstock‐Guttman, B. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a032003 · Cited by 178
Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis
Ontaneda, D., Tallantyre, E. C., Kalinčík, T., Planchon, S. M., & Evangelou, N. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30151-6 · Cited by 178
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
Nash, R. A., Hutton, G. J., Racke, M. K., Popat, U., Devine, S. M., Steinmiller, K. C., Griffith, L. M., Muraro, P. A., Openshaw, H., Sayre, P. H., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003660 · Cited by 167
Self-citationDisease modifying therapies for relapsing multiple sclerosis
Wingerchuk, D. M., & Weinshenker, B. G. (2016) · BMJ · doi:10.1136/bmj.i3518 · Cited by 174
Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm
Giovannoni, G. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000561 · Cited by 170
Self-citationUpdates and Advances in Multiple Sclerosis Neurotherapeutics
Amin, M., & Hersh, C. M. (2022) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0058 · Cited by 180
Kalinčík, T., Brown, J. W. L., Robertson, N. P., Willis, M., Scolding, N. J., Rice, C. M., Wilkins, A., Pearson, O. R., Ziemssen, T., Hutchinson, M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30007-8 · Cited by 164
Self-citationZhang, X., Tao, Y., Chopra, M., Ahn, M., Marcus, K. L., Choudhary, N. R., Hongtu Zhu, B., & Markovic‐Plese, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301926 · Cited by 162
Initial high-efficacy disease-modifying therapy in multiple sclerosis
Buron, M. D., Chalmer, T. A., Sellebjerg, F. T., Barzinji, I., Sindberg, D. B., Christensen, J. R., Christensen, M. K., Hansen, V., Illés, Z., Jensen, H. B., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010135 · Cited by 163
Promoting remyelination in multiple sclerosis
Cunniffe, N. G., & Coles, A. J. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09421-x · Cited by 172
Self-citationBrain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options
Andravizou, A., Dardiotis, E., Artemiadis, A., Sokratous, M., Siokas, V., Tsouris, Z., Aloizou, A., Nikolaidis, I., Bakirtzis, C., Tsivgoulis, G. K., et al. (2019) · Autoimmunity Highlights · doi:10.1186/s13317-019-0117-5 · Cited by 167
Immunological Aspects of Approved MS Therapeutics
Rommer, P. S., Milo, R., Han, M. H., Satyanarayan, S., Sellner, J., Hauer, L., Illés, Z., Warnke, C., Laurent, S. A., Weber, M. S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01564 · Cited by 161
Rae-Grant, A. D., Day, G. S., Marrie, R. A., Rabinstein, A. A., Cree, B., Gronseth, G., Haboubi, M., Halper, J., Hosey, J. P., Jones, D., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005345 · Cited by 158
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
Ceronie, B., Jacobs, B. M., Baker, D., Dubuisson, N., Mao, Z., Ammoscato, F., Lock, H., Longhurst, H. J., Giovannoni, G., & Schmierer, K. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8830-y · Cited by 149
Self-citationGholamzad, M., Ebtekar, M., Ardestani, M. S., Azimi, M., Mahmodi, Z., Mousavi, M. J., & Aslani, S. (2018) · Inflammation Research · doi:10.1007/s00011-018-1185-0 · Cited by 161
Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting
Tur, C., Moccia, M., Barkhof, F., Chataway, J., Sastre‐Garriga, J., Thompson, A. J., & Ciccarelli, O. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.171 · Cited by 146
Epstein, D. J., Dunn, J., & Deresinski, S. C. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy174 · Cited by 147
The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis
Mallucci, G., Peruzzotti‐Jametti, L., Bernstock, J. D., & Pluchino, S. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.02.003 · Cited by 153
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Freeman, L. A., Longbrake, E. E., Coyle, P. K., Hendin, B. A., & Vollmer, T. R. (2022) · CNS Drugs · doi:10.1007/s40263-022-00965-7 · Cited by 155
Established and novel disease‐modifying treatments in multiple sclerosis
Cross, A. H., & Naismith, R. T. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12203 · Cited by 142
Both cladribine and alemtuzumab may effect MS via B-cell depletion
Baker, D., Herrod, S. S., Álvarez-González, C., Zalewski, L., Albor, C., & Schmierer, K. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000360 · Cited by 140
Update on Disease-Modifying Therapies for Multiple Sclerosis
Vargas, D. L., & Tyor, W. R. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2016-000339 · Cited by 138
Therapeutic Advances in Multiple Sclerosis
Yang, J. H., Rempe, T., Whitmire, N., Dunn‐Pirio, A., & Graves, J. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.824926 · Cited by 148
Svenningsson, A., Frisell, T., Burman, J., Salzer, J., Fink, K., Hallberg, S., Hambraeus, J., Axelsson, M., Nimer, F. A., Sundström, P., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00209-5 · Cited by 151
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
Pakpoor, J., Disanto, G., Altmann, D. R., Pavitt, S. H., Turner, B. P., Marta, M., Juliusson, G., Baker, D., Chataway, J., & Schmierer, K. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000158 · Cited by 134
Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review
Merkel, B., Butzkueven, H., Traboulsee, A. L., Havrdová, E., & Kalinčík, T. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.04.010 · Cited by 134
Early Aggressive Treatment Approaches for Multiple Sclerosis
Simpson, A. C., Mowry, E. M., & Newsome, S. D. (2021) · Current Treatment Options in Neurology · doi:10.1007/s11940-021-00677-1 · Cited by 138
Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations
Freedman, M. S., Devonshire, V. A., Duquette, P., Giacomini, P. S., Giuliani, F., Levin, M. C., Montalbán, X., Morrow, S. A., Oh, J., Rotstein, D., et al. (2020) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2020.66 · Cited by 137
Kalincik, T., Spelman, T., Trojano, M., Duquette, P., Izquierdo, G., Grammond, P., Lugaresi, A., Hupperts, R., Cristiano, E., van Pesch, V., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063480 · Cited by 128
Aggressive multiple sclerosis: proposed definition and treatment algorithm
Rush, C., MacLean, H. J., & Freedman, M. S. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.85 · Cited by 128
Dulamea, A. O. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-47861-6_7 · Cited by 128
New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis
English, C., & Aloi, J. J. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.03.001 · Cited by 132
GM-CSF in Neuroinflammation: Licensing Myeloid Cells for Tissue Damage
Croxford, A. L., Spath, S., & Becher, B. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.08.004 · Cited by 132
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Piehl, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13215 · Cited by 125
The immunological function of CD52 and its targeting in organ transplantation
Zhao, Y., Su, H., Shen, X., Du, J., Zhang, X., & Zhao, Y. X. (2017) · Inflammation Research · doi:10.1007/s00011-017-1032-8 · Cited by 120
Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS
Akgün, K., Kretschmann, N., Haase, R., Proschmann, U., Kitzler, H. H., Reichmann, H., & Ziemssen, T. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000555 · Cited by 124
Fogarty, E., Schmitz, S., Tubridy, N. J., Walsh, C., & Barry, M. G. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.06.001 · Cited by 119
Pardo, G., & Jones, D. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8594-9 · Cited by 124
Thinking outside the box: non-canonical targets in multiple sclerosis
Bierhansl, L., Hartung, H., Aktaş, O., Ruck, T., Roden, M., & Meuth, S. G. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00477-5 · Cited by 125
Self-citationEfficacy classification of modern therapies in multiple sclerosis
Samjoo, I. A., Worthington, E., Drudge, C., Zhao, M., Cameron, C. G., Häring, D. A., Stoneman, D., Klotz, L., & Adlard, N. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0267 · Cited by 120
Axisa, P., & Hafler, D. A. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000319 · Cited by 126
Guidelines on the use of irradiated blood components
Foukaneli, T., Kerr, P., Bolton‐Maggs, P. H. B., Cardigan, R. A., Coles, A. J., Gennery, A. R., Jane, D., Kumararatne, D. S., Manson, A. L., New, H. V., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17015 · Cited by 113
Self-citationDefining and scoring response to IFN-β in multiple sclerosis
Sormani, M. P., & Stefano, N. D. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.146 · Cited by 111
Therapies for multiple sclerosis: translational achievements and outstanding needs
Haghikia, A., Hohlfeld, R., Gold, R., & Fugger, L. H. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.03.004 · Cited by 105
Risk of relapse phenotype recurrence in multiple sclerosis
Kalinčík, T., Buzzard, K. A., Jokubaitis, V., Trojano, M., Duquette, P., Izquierdo, G., Girard, M., Lugaresi, A., Grammond, P., Grand’Maison, F., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514528762 · Cited by 108
New management algorithms in multiple sclerosis
Sørensen, P. S. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000096 · Cited by 106
Rae-Grant, A. (2019) · Neurology · doi:10.1212/wnl.0000000000008376 · Cited by 104
Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort
Willis, M., Harding, K. E., Pickersgill, T. P., Wardle, M., Pearson, O. R., Scolding, N. J., Smee, J., & Robertson, N. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515614092 · Cited by 101
Metadata
- Authors
- Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., Brinar, V. V., Giovannoni, G., Stojanovic, M., Ertik, B. I., Lake, S. L., Margolin, D. H., Panzara, M. A., & Compston, D. A. S.
- Affiliations
- Cleveland Clinic (US)
- University of Cambridge (GB)
- Montreal Neurological Institute and Hospital (CA)
- Lyon 1 Université (FR)
- Central Texas Neurology Consultants (US)
- Heinrich Heine University Düsseldorf (DE)
- Medical University of Lodz (PL)
- Brigham and Women's Hospital (US)
- University Hospital Centre Zagreb (HR)
- Queen Mary University of London (GB)
- Clinical Centre of Kragujevac (RS)
- Corresponding author
- Cohen, Jeffrey A
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 380
- Issue
- 9856
- Pages
- 1819-1828
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2148766438
- Cited by
- 1,205
- References
- 39
- Citations by year
- 2026: 25 · 2025: 52 · 2024: 66 · 2023: 71 · 2022: 70 · 2021: 77 · 2020: 109 · 2019: 112 · 2018: 108 · 2017: 120 · 2016: 112 · 2015: 104 · 2014: 85 · 2013: 83 · 2012: 6
- FWCI
- 64.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0508-10335)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- alemtuzumab, interferon beta-1a, relapsing-remitting multiple sclerosis, first-line therapy, anti-CD52 monoclonal antibody, relapse rate, disability progression, disease-modifying therapy, treatment safety, treatment-naive patients, relapse-free survival, time to treatment discontinuation, adverse events, immunosuppression
- MeSH terms
- Interferon beta-1a, Alemtuzumab, Adjuvants, Immunologic, Administration, Cutaneous, Adolescent, Adult, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Recurrence, Treatment Outcome, Interferon-beta, Disease-Free Survival, Multiple Sclerosis, Relapsing-Remitting, Kaplan-Meier Estimate, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
